Related Experiment Video
Updated: Apr 11, 2026
08:07
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
7.8K
Advances in emerging drugs for osteosarcoma
Claudia Maria Hattinger1, Marilù Fanelli, Elisa Tavanti
1a 1 Rizzoli Orthopaedic Institute, Laboratory of Experimental Oncology , Bologna, Italy.
Expert Opinion on Emerging Drugs
|May 30, 2015
Summary
New treatments are needed for osteosarcoma (OS), a common bone cancer with limited success in current therapies. Research is exploring novel targeted drugs and strategies to improve patient outcomes and survival rates.
Area of Science:
- Oncology
- Orthopedic Oncology
- Cancer Therapeutics
Background:
- Osteosarcoma (OS) is the most prevalent primary malignant bone tumor.
- Current treatments (chemotherapy and surgery) yield cure rates of 60-65% for primary tumors and only 20-25% for recurrent disease.
- Improved therapeutic strategies are crucial for enhancing patient prognosis.
Purpose of the Study:
- To review emerging and clinically evaluated therapeutic approaches for osteosarcoma.
- To highlight novel targeted therapies under investigation for high-grade OS.
- To provide an overview of the current landscape of osteosarcoma treatment development.
Main Methods:
- Comprehensive literature search of updated databases.
- Focus on clinical trials and reviews of targeted therapies for high-grade OS.
- Analysis of ongoing research in osteosarcoma treatment.
Main Results:
- Osteosarcoma exhibits significant heterogeneity, leading to variable treatment responses.
- A single therapeutic agent is unlikely to be effective for all patients.
- Ongoing clinical trials (Phase I/II/III) are evaluating promising novel agents and strategies.
Conclusions:
- Personalized medicine approaches are essential for osteosarcoma treatment.
- Validation of new therapeutic strategies alongside predictive biomarkers is necessary.
- Future research holds promise for identifying more effective and safer osteosarcoma therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.2K
02:57Targeted Cancer Therapies
1.8K
1.8K
02:49Cancer Therapies
10.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.7K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
02:56Treatment Resistent Cancers
1.5K
1.5K
03:03mTOR Signaling and Cancer Progression
5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.1K